1、Letter toSHAREHOLDERS20242To My FellowSHAREHOLDERS,ON THE COVER:Jrgen(top left),living with myelomaGina(top right),living with colorectal cancerMJ(bottom left),living with pediatric B-cell acute lymphoblastic leukemiaAngie(bottom right),living with cardiovascular diseaseRobert A.Bradway Chairman and

2、 Chief Executive OfficerAmgen Inc.Amgen delivered strong results in 2024.We reached millions of patients worldwide with our life-changing medicines,advanced the broadest and deepest pipeline in our history,and positioned ourselves to deliver attractive long-term growth.In 2024,total revenues grew 19

3、%to a record$33.4 billion,driven by 23%volume growth,as our medicines reached more patients worldwide.Non-GAAP earnings per share increased 6%to$19.84.1 We increased our dividend per share by 6%,marking our 13th consecutive annual dividend increase,and we generated$10.4 billion1 of free cash flow.Un

4、like some of our competitors that are heavily reliant on one or two products,Amgen exited 2024 with 14 blockbuster products,defined as those with an annualized run rate of over$1 billion in sales.2 Furthermore,we saw record sales across 21 products,with ten delivering at least double-digit sales gro

5、wth,including Repatha,TEZSPIRE,EVENITY,BLINCYTO,and TAVNEOS.These measures provide support for the strong foundation on which our growth is based.We invested a record$6.0 billion in R&D,up 25%from the prior year,3 and we have numerous potential first-or best-in-class medicines moving rapidly through

6、 our pipeline to treat obesity and obesity-related conditions,cancer,heart disease,and many other serious illnesses.Were also continuing to invest in growing our manufacturing network to keep pace with the demand for our products,opening our state-of-the-art manufacturing site in central Ohio and an